SEC Company Response from BIOCRYST PHARMACEUTICALS INC (BCRX) (CIK 0000882796) (BCRX) — Nov 30, 2010

BIOCRYST PHARMACEUTICALS INC (BCRX) (CIK 0000882796)
Date: Nov. 30, 2010 · CIK: 0000882796 · Accession: 0000950123-10-109837

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-23186

Date

November 30, 2010

Author

/s/ Robyn Zolman

Form

CORRESP

Company

BIOCRYST PHARMACEUTICALS INC (BCRX) (CIK 0000882796)

Letter

VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission Filed March 9, 2010 Definitive Proxy Statement on Schedule 14A Filed April 6, 2010 File No. 000-23186

Dear Ms. Zukin:

On behalf of BioCryst Pharmaceuticals, Inc. (the “Company”) this letter confirms that as discussed with you today, the Company will respond to the Staff’s November 16, 2010 letter to the Company on or before December 15, 2010.

Sincerely,
/s/ Robyn Zolman

Show Raw Text

CORRESP
1
filename1.htm

corresp

    Robyn Zolman

    November 30, 2010

    Direct: 303.298.5740

    Fax: 303.313.2830

    RZolman@gibsondunn.com

    Client: C 12412-00001

VIA EDGAR

Ms. Rose Zukin

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, NE

Washington, D.C. 20549

    Re:

    BioCryst Pharmaceuticals, Inc.

Form 10-K for the year ended December 31, 2009

Filed March 9, 2010

Definitive Proxy Statement on Schedule 14A

Filed April 6, 2010

File No. 000-23186

Dear Ms. Zukin:

On behalf of BioCryst Pharmaceuticals, Inc. (the “Company”) this letter confirms that as discussed
with you today, the Company will respond to the Staff’s November 16, 2010 letter to the Company on
or before December 15, 2010.

Sincerely,

/s/ Robyn Zolman

Robyn Zolman

REZ/rez

    cc:

    Alane Barnes, BioCryst Pharmaceuticals, Inc.

Brian Lane, Gibson, Dunn & Crutcher LLP

SecProbe.io